Loading clinical trials...

Effect of REST in the Alzheimer Disease Continuum | Clinical Trials | Clareo Health

COMPLETED

Effect of REST in the Alzheimer Disease Continuum

Effect of REST on Cognitive Function and Hippocampus in the Alzheimer Disease Continuum

NCT03884023•Dongzhimen Hospital, Beijing

Summary

The investigators assume that REST gene polymorphism affects REST protein concentration, and REST protein concentration in peripheral blood is related to cognitive function and hippocampus. In this current study, REST protein content and gene polymorphism will be obtained in peripheral blood in AD and normal control. The effect of REST gene polymorphism on REST protein concentration will be discovered.The relationship between REST protein concentration and cognitive function will be found, as well as the relationship between REST protein concentration and hippocampus.

Detailed Description

Repressor element silencing transcription factor(REST), also known as neuron-restrictive silencer factor (NRSF) is a zinc finger protein of 121 kD and belongs to the Gli-Kruppel family with transcriptional regulation.This will be a Case-Crossover research. Consecutive participants will be divided into Alzheimer's disease dementia group, mild cognitive impairment due to Alzheimer's disease group and normal control group according to inclusion criteria of this research. Peripheral blood samples will be retained to detect REST gene polymorphisms and protein concentrations. Participants perform neuropsychological tests to assess cognitive function. Medial temporal atrophy scale is used to describe hippocampus. Differences in the mean or proportions between these 3 groups will be checked by t test or test. The relationship between REST protein concentration and cognitive function will be estimated, as well as the relationship between REST protein concentration and hippocampus.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. No active neurological and mental illness;
•2. No use of psychotropic drugs;
•3. Patients may have diseases, but these diseases and their treatment have no effect on cognition (MMSE\>28);
•4. Single cognitive field test was normal;
•5. The clinical dementia rating scale is normal (CDR=0);
•6. Aged 55-85, male or female;
•7. Sufficient vision and hearing for neuropsychological tests;
•8. Have a certain level of education, can read and write simple sentences;
•9. Sign the informed consent.
•1. Complained of memory loss or/and confirmed by others;
+18 more criteria

Exclusion Criteria

•1. Meet the DSM-IV diagnostic criteria of dementia;
•2. Obvious cerebrovascular diseases in MRI;
•3. Depression or other mental illnesses that meet the DSM-IV criteria in the past 2 years, the simplified version of the Geriatric Depression Scale (GDS-15) ≥ 8 ;
•4. A history of alcohol or substance abuse or addiction in the past 2 years;
•5. History of schizophrenia;
•6. Any obvious neurological diseases, such as Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumors, progressive supra nuclear paralysis, epilepsy, chronic subdural hematoma, multiple sclerosis, severe head trauma with persistent neurological impairment or known structural brain abnormalities;
•7. In investigator's impression, the subject cannot cooperate with the research procedure;
•8. Other known systemic diseases that cause dementia (such as hypothyroidism, folate or vitamin B deficiency, neurosyphilis, HIV infection).
•1. With severe cerebrovascular disease, defined as a history of stroke temporal associated with the occurrence or deterioration of cognitive impairment; Or the occurrence of multiple or severe infarction or severe white matter high signal;
•2. Have the core characteristics of Lewy body dementia rather than dementia itself;
+5 more criteria

Locations (1)

Dongzhimen Hospital,Beijing University of Chinese Medicine

Beijing, Beijing Municipality, China

Key Dates

Start Date

June 28, 2019

Primary Completion Date

November 30, 2020

Completion Date

November 30, 2020

Last Updated

March 23, 2022

Enrollment

300

ACTUAL participants

Conditions

Alzheimer's Disease

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 23, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of REST in the Alzheimer Disease Continuum

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia